Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

138.31USD
1:30am IST
Change (% chg)

$4.97 (+3.73%)
Prev Close
$133.34
Open
$134.13
Day's High
$138.80
Day's Low
$132.37
Volume
211,954
Avg. Vol
250,807
52-wk High
$167.24
52-wk Low
$73.59

Select another date:

Wed, Jul 8 2020

BRIEF-Alnylam Pharmaceuticals And Taiba Group Partner To Commercialize RNAi Therapeutics In The Gulf States

* ALNYLAM PHARMACEUTICALS AND TAIBA GROUP PARTNER TO COMMERCIALIZE RNAI THERAPEUTICS IN THE GULF STATES

BRIEF-Alnylam Reports New 12-Month Interim Data From The Envision Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

* ALNYLAM REPORTS NEW 12-MONTH INTERIM DATA FROM THE ENVISION PHASE 3 STUDY OF GIVOSIRAN IN ACUTE HEPATIC PORPHYRIA

BRIEF-Alnylam Announces Publication Of Phase 3 Study Results For Givosiran In The New England Journal Of Medicine

* ALNYLAM ANNOUNCES PUBLICATION OF ENVISION PHASE 3 STUDY RESULTS FOR GIVOSIRAN IN THE NEW ENGLAND JOURNAL OF MEDICINE

BRIEF-Alnylam Presents Positive Phase 3 Results From ILLUMINATE-A Study Of Lumasiran

* ALNYLAM PRESENTS POSITIVE PHASE 3 RESULTS FROM ILLUMINATE-A STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1

BRIEF-Alnylam Announces U.S. FDA Has Granted Priority Review Of Lumasiran New Drug Application For Treatment Of Primary Hyperoxaluria Type 1

* ALNYLAM ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION HAS GRANTED PRIORITY REVIEW OF THE LUMASIRAN NEW DRUG APPLICATION FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1

BRIEF-Alnylam Pharmaceuticals Qtrly Loss Per Share Of $1.62

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-Alnylam Pharmaceuticals Reports Q1 2020 Financial Results

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

UPDATE 2-Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

May 4 Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

Select another date: